A Phase I, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Diseases and Conditions Researched
Bladder; Breast - Female; Colon; Lung; Melanoma, skin; Other Endocrine System; Other Respiratory and Intrathoracic Organs; Other Urinary; Ovary; Rectum; Stomach
What is the purpose of this trial?
This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications.
Click here for detailed participation information for this trial.
|Sponsor:||EMD Serono, Inc.|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.